HC Wainwright set a $37.00 price objective on Audentes Therapeutics (NASDAQ:BOLD) in a research note published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also issued reports on the company. Zacks Investment Research upgraded Audentes Therapeutics from a hold rating to a buy rating and set a $37.00 target price on the stock in a research report on Thursday, March 8th. William Blair reiterated a buy rating on shares of Audentes Therapeutics in a research report on Friday. Raymond James Financial reiterated a hold rating on shares of Audentes Therapeutics in a research report on Thursday, January 4th. ValuEngine lowered Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, BMO Capital Markets initiated coverage on Audentes Therapeutics in a research report on Tuesday, December 5th. They set an outperform rating and a $35.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Audentes Therapeutics currently has an average rating of Buy and an average price target of $35.56.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $34.80 on Friday. The company has a market cap of $1,230.00 and a P/E ratio of -10.00. Audentes Therapeutics has a one year low of $13.90 and a one year high of $41.80.
In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of the firm’s stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 421,638 shares of the firm’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.17, for a total value of $14,829,008.46. The disclosure for this sale can be found here. Insiders have sold a total of 1,087,707 shares of company stock worth $38,055,301 in the last quarter. Insiders own 47.30% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC lifted its holdings in Audentes Therapeutics by 10.4% in the 3rd quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after purchasing an additional 73,809 shares in the last quarter. Mckinley Capital Management LLC Delaware purchased a new position in Audentes Therapeutics in the 3rd quarter valued at $1,333,000. New York State Common Retirement Fund lifted its holdings in Audentes Therapeutics by 299.9% in the 2nd quarter. New York State Common Retirement Fund now owns 16,400 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 12,299 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after purchasing an additional 383,837 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Audentes Therapeutics by 1,086.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after purchasing an additional 12,435 shares in the last quarter. Institutional investors own 67.35% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3258514/audentes-therapeutics-bold-given-a-37-00-price-target-by-hc-wainwright-analysts.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.